Today, Ocumetics has entered the history books. Nearly two decades of relentless innovation, bold ambition, and unwavering belief have led to this defining moment: the first-in-human implantation of the Ocumetics Lens.
What many once thought impossible is now reality. This achievement is not the work of one person or one idea, but the result of years of persistence by an extraordinary team of scientists, engineers, clinical advisors, and partners who refused to let go of a vision to transform human sight.
This is more than a milestone; it is a turning point for ophthalmology and for millions of people worldwide who are waiting for new solutions. And while we celebrate this historic success, we know our mission is far from complete. With more determination than ever, we move forward to deliver the Ocumetics Lens to patients everywhere and reshape the future of vision.
Best regards
Dean Burns
President, CEO and Director
Ocumetics Technology
Ocumetics Director and CEO, Dean Burns, walks us through relevant topics including: First-in-human study timing Remaining steps to first-in-human study Q&A session Thanks to everyone who joined us for the Webinar. It was an amazing turnout, and it was great to hear your questions and comments. We look forward to hosting more webinars in the
Today marks a defining moment in the history of Ocumetics—and in the future of vision restoration worldwide. It is with great pride and anticipation that I share we are now entering the final stages before our First-In-Human (FIH) clinical study for the Ocumetics Lens. This is more than a corporate milestone; it is the beginning
Ocumetics Director and CEO, Dean Burns, walks through relevant topics including:1. Development Update on the Ocumetics IOL2. Remaining steps to first-in-human study3. Q&A session Thanks to everyone who joined us for the Webinar. It was an amazing turnout, and it was great to hear your questions and comments. We look forward to hosting more webinars in
Dear Stakeholders, I want to take a moment to update you on our progress with the development of Ocumetics’ accommodative intraocular lens (AIOL), which will soon undergo its first-in-human (FIH) trials. As you know, we are committed to pioneering advanced ophthalmic technologies that will transform the way we treat cataracts and other vision conditions. In
